Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor - Wikidata - thesis-toulmin - TriplyDB

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

http://www.wikidata.org/entity/Q28238398

about

The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison Milnacipran: a unique antidepressant?The noradrenergic paradox: implications in the management of depression and anxiety Levomilnacipran for the treatment of major depressive disorder: a review Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats Desvenlafaxine.Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice.Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.Desvenlafaxine in the treatment of major depressive disorder.Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.Duloxetine for the management of fibromyalgia syndrome.The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study Pharmacology update: tapentadol for neuropathic pain.Metabolomic identification of biochemical changes induced by fluoxetine and imipramine in a chronic mild stress mouse model of depression.Monoamine reuptake inhibitors in Parkinson's disease.A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.Antidepressant efficacy and side-effect burden: a quick guide for clinicians.The solute carrier 6 family of transporters Emerging drugs in neuropathic pain.The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.Desvenlafaxine: another "me too" drug?Receptor and transporter binding and activity profiles of albiflorin extracted from Radix paeoniae Alba.Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause.A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.Chiral determination of antidepressant drugs and their metabolites in biological samples.Emerging drugs for major depressive disorder.Use of preoperative antidepressants is not associated with postoperative hospital length of stay.Desvenlafaxine for the treatment of major depressive disorder.Pharmacokinetics of antidepressants in patients with hepatic impairment.The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia.The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety.

P2860

Q21132285-DBC1B7AF-08CE-4EE9-B733-77EEDDCAB0D4 Q24567525-EF9AABF7-47C0-45CB-9050-069B21AB69BE Q24610271-FDBB5BCD-59BE-48EB-B304-F969BDE1092C Q26752868-C9D21E85-CFC4-4FBC-9B27-0013940300CA Q28083216-ED84CA28-8366-4F89-8A03-25A9F54C1530 Q28539344-0E97DA87-DC7C-4B71-B339-09DEFA5E1D36 Q33574492-8D1EA88B-4872-4C35-995B-6B5F1372B8A1 Q33824509-48EA1D0B-1D4F-4A4A-8FE3-1530D3BF28E2 Q33980047-4C104BA7-1A58-4418-88A8-F12A3AA783C2 Q34163718-9833AAE6-A567-40B5-9F2E-F83E9B0D3151 Q34234091-A18D1CB1-AE33-4A13-A7FF-C3EDEE570955 Q34355963-AEF5AF0F-F5BA-4DA9-A35B-667B866BBCEE Q34418217-7A403895-DF0D-4C27-B258-727D0E8F1219 Q34531579-8A387405-2BB6-499B-BCEA-C16630983B96 Q34635669-709FC4E9-CD72-4D4E-A434-834148BA870B Q35157192-A25C514D-C717-498C-9A4B-4F1572BFAFA6 Q35165280-5E8ED691-E6D8-4C5D-B6C5-61AA23F561AF Q35252115-E6030104-4792-4F94-B2DE-16289B969DE3 Q36243042-907F2D2D-7F1E-464C-B720-F1D99661A557 Q36346899-5102F52E-8610-4885-BB56-711F66BEAC8E Q36758590-38C41B89-0B2D-4764-B272-A1479209D74E Q36781720-54F8B68E-F1FC-43C2-BC34-C7F19B01ACCE Q37077152-523F69EB-00C3-456C-BF5C-ABD36D0BCDBE Q37177212-612DE1F0-A32E-4784-8191-65FA4C8B9FB7 Q37242256-DE91EE1F-F8B4-4E6D-9BBD-57E1890DC287 Q37267201-5F5B7B12-BB44-44E8-94D2-E5CFA5FE08C7 Q37352035-8F605AE3-F9B2-437A-A96A-5A416728501D Q37404814-54562905-6816-4180-9BE4-2D1BE1DD75E2 Q37630556-09A5B716-29B0-4916-88AE-15FE66FD9454 Q37651165-AD39589A-1A2B-4F60-8396-759913AFBA46 Q37682552-6AF10A5E-6E15-4645-8A7A-EF3319CCDEF9 Q37810213-D795ED29-946D-411A-9DAE-58CC89AF60A4 Q37984619-D5E1FEB8-A2F6-4CA3-857F-637BB8E99ABC Q38154521-E87F37A0-FB26-4547-97A8-B0E7EEABD4C6 Q38219037-881E5887-C216-4EB8-8329-44B632DDDFAC Q38253564-7D97CE55-21AD-45C9-9A60-C636B472EDB3 Q38394430-5830EBD8-F568-4A34-BABA-7C1D1464006B Q38494698-E875F313-8BB4-4AB7-AED6-4AEBEA7BEE34 Q38786561-EA54E7C2-45EB-426E-BDCE-6C5CB933F4AD Q38847601-587C1447-D17B-4F13-A981-55396925D7B0

P2860

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

http://www.wikidata.org/entity/Q28238398

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@ast

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@en

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@nl

type

label

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@ast

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@en

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@nl

prefLabel

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@ast

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@en

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@nl

P1433

Q28238398-6F04FC90-E763-4EAF-9691-610273D4729E

P1476

Q28238398-984D686E-221B-4D4F-9255-66CB11027F66

P2093

Q28238398-117C6392-04E1-421D-98AC-240A3562AE49

Q28238398-24DEA750-F380-4B1D-8B40-5A0A890D5066

Q28238398-44BEBE9E-56AF-4298-B89C-0DA6A86197FD

Q28238398-56F5CE2F-FFEF-44BA-A67E-7CBFDCCEBE8F

Q28238398-81682950-29DD-4303-8432-A461C155B797

Q28238398-E48EC950-97D6-43AB-919B-444EBACE9AB0

Q28238398-FD6424B4-0785-4950-925B-AC97006C591C

P304

Q28238398-6707D697-839A-42AB-A728-EFBD7D048482

P31

Q28238398-D874EF04-7D99-48BF-8B06-9AB88E8B0927

P3181

Q28238398-B8550050-1074-41B9-AD41-66A936190768

P356

Q28238398-899B644D-C2C0-439E-9223-5329CD7FAC71

P407

Q28238398-4F2A743C-FB25-475E-B63A-9E5DE072C2C0

P433

Q28238398-15F764B7-9382-407D-924F-9EF68D6BE0B8

P478

Q28238398-9697465F-2DD0-4F9F-9CA6-AECCEB8763C2

P577

Q28238398-BB421F22-4ED6-41E3-91E1-0884F2E3E583

P5875

Q28238398-894310DD-6FE1-4F46-9BD7-602B40FABF46

P698

Q28238398-D22D736F-9E42-4D27-B2FF-5633DE5A473E

P921

Q28238398-867aa4f3-6de2-4b52-b951-5bd911aa5875

Q28238398-dcbe3c00-c5f3-4616-976d-b9c0c9341947

P3181

P356

JPET.106.103382

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

@en

P2093

Chad E Beyer

http://www.w3.org/2001/XMLSchema#string

Darlene C Deecher

http://www.w3.org/2001/XMLSchema#string

Grace Johnston

http://www.w3.org/2001/XMLSchema#string

Jenifer Bray

http://www.w3.org/2001/XMLSchema#string

M Abou-Gharbia

http://www.w3.org/2001/XMLSchema#string

S Shah

http://www.w3.org/2001/XMLSchema#string

Terrance H Andree

http://www.w3.org/2001/XMLSchema#string

P304

657-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2811772

http://www.w3.org/2001/XMLSchema#string

P356

10.1124/JPET.106.103382

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

318

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7104664

http://www.w3.org/2001/XMLSchema#string

P698

16675639

http://www.w3.org/2001/XMLSchema#string

P921